// App-Quantinova.ai

e23222 : Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).

Researchers

Presenter

  • Yasir Elamin

Principal Investigators

  • Dianren Xia

  • Kathryn A. Gold

  • Lauren Averett Byers

  • You Hong Fan

  • Lixia Diao

  • Jing Wang

  • Uma Giri

  • Jayanthi Gudikote

  • Hai T. Tran

  • John Heymach

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Molecular Health Inc., The Woodlands, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • Molecular Health Gmb

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Refametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved